| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Insulin, Intact, LC/MS/MS
Test Code93103
Alias/See Also
LAB527
Dr. Erika Downs' orders = Insulin Fasting
Dr. Erika Downs' orders = Insulin Fasting
CPT Codes
83525
Preferred Specimen
0.5 mL serum
Patient Preparation
Overnight fasting is required
Minimum Volume
0.3 mL
Instructions
Allow serum samples to clot completely before centrifugation.
Transport Container
Transport tube
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 24 hours
Refrigerated: 28 days
Frozen 28 days
Refrigerated: 28 days
Frozen 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis • Received room temperature
Methodology
Immunocapture Liquid Chromatography/Tandem Mass Spectrometry
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Mon-sat
Report Available
3-5 days
Reference Range
≤16 uIU/mL
Clinical Significance
Insulin is a key hormone involved in the control of blood glucose and regulation of fatty acid metabolism. Insulin measurement is primarily used to evaluate the cause of hypoglycemia. Inappropriately elevated insulin in blood (hyperinsulinemia) is associated with hypoglycemia(1) or in disorders linked to hyperglycemia, such as metabolic syndrome(2). Causes of hyperinsulinemia include insulinoma, insulin resistance, noninsulinoma pancreatogenous hypoglycemia syndrome, insulin antibodies, surreptitious insulin administration or other drug-induced hyperinsulinism (e.g., sulfonyl urea), incretin effects after bariatric surgery, and congenital hyperinsulinism. Insulin (test code 561) immunoassay can be used to evaluate the etiology of hypo- or hyperglycemia but is not equivalent to the LC/MS/MS test. Combined with LC/MS/MS measurement of C-peptide in the Cardio IQ Insulin Resistance Panel with Score (test code 36509), the assay can also help evaluate the likelihood that an individual has clinically significant insulin resistance or help in differential diagnosis (e.g., insulinoma versus exogenous insulin administration(3). The results of this test should be interpreted in the context of pertinent clinical history and physical examination findings.
References
1. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709-728. doi:10.1210/jc.2008-1410
2. Kelly CT, Mansoor J, Dohm GL, et al. Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. Surgery. 2014;156(2):405-411. doi:10.1016/j.surg.2014.04.028
3. Abbasi F, Shiffman D, Tong CH, et al. Insulin resistance probability scores for apparently healthy individuals. J Endocr Soc. 2018;2(9):1050-1057. doi:10.1210/js.2018-00107
References
1. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709-728. doi:10.1210/jc.2008-1410
2. Kelly CT, Mansoor J, Dohm GL, et al. Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. Surgery. 2014;156(2):405-411. doi:10.1016/j.surg.2014.04.028
3. Abbasi F, Shiffman D, Tong CH, et al. Insulin resistance probability scores for apparently healthy individuals. J Endocr Soc. 2018;2(9):1050-1057. doi:10.1210/js.2018-00107
Performing Laboratory
| Quest Diagnostics Nichols Institute-San Juan Capistrano, CA |
| 33608 Ortega Highway |
| San Juan Capistrano, CA 92675-2042 |